Skip to content

Clinical Outcomes With Electroconvulsive Therapy: Insights From Computational Modelling

Clinical Outcomes With Electroconvulsive Therapy: Insights From Computational Modelling

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03297411
Enrollment
15
Registered
2017-09-29
Start date
2017-10-10
Completion date
2022-06-22
Last updated
2018-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Keywords

electroconvulsive therapy, computer modelling

Brief summary

This study will generate new information on how to optimise brain targets with ECT stimulation.

Detailed description

This study will differentiate the brain regions which are related to the effectiveness of electroconvulsive therapy (ECT) as a treatment, from the brain regions associated with memory impairment, with ECT stimulation. This will be done by 1) testing effects on memory of 4 different forms of ECT, which stimulate the brain differently; 2) in a subset of participants, use computer modelling to assess the pattern of brain stimulation with the 4 forms of ECT, and match these results to memory outcomes.

Interventions

PROCEDUREBrief Temporoparietal ECT

Electroconvulsive Therapy (Brief pulse width, Temporoparietal) The intervention in this study is different combinations of pulse width and ECT electrode placements.

PROCEDUREUltrabrief Temporoparietal ECT

Electroconvulsive Therapy (Ultrabrief pulse width, Temporoparietal) The intervention in this study is different combinations of pulse width and ECT electrode placements.

PROCEDUREBrief Frontoparietal ECT

Electroconvulsive Therapy (Brief pulse width, Frontoparietal) The intervention in this study is different combinations of pulse width and ECT electrode placements.

PROCEDUREUltrabrief Frontoparietal ECT

Electroconvulsive Therapy (Ultrabrief pulse width, Frontoparietal) The intervention in this study is different combinations of pulse width and ECT electrode placements.

Sponsors

Wesley Mission
CollaboratorOTHER
The University of New South Wales
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

Both participants and the outcome assessor will be blinded.

Intervention model description

Each participant will be randomly allocated to a sequence of treatments using designs for crossover studies with fewer periods (3) than treatments (4) involving two sets of ECT electrode placements and two sets of pulse width.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Aged ≥18 years; right-handed * DSM-5 Major Depressive Episode * Prescribed with a course of ECT

Exclusion criteria

* Diagnosis (as defined by DSM-V) of psychotic disorder (apart from Major Depressive Episode with Psychotic features), current drug or alcohol abuse or dependence; * ECT treatments in last 3 months from a prior course of ECT; * Score \<23 on the Montreal Cognitive Assessment Battery (MoCA); * Past or current neurological illness or injury, medical illness which may significantly affect neuropsychological function; * Inability to give informed consent or comply with study procedures; or * Not having worked or studied in an English speaking background (to ensure validity of neuropsychological testing). * Not be claustrophobic (if having an MRI brain scan). * Not have any metal in your head or body (if having an MRI brain scan). * Likely non response to RUL forms of ECT, as indicated by past non response to RUL ECT

Design outcomes

Primary

MeasureTime frameDescription
HVLT-RApproximately 30 min after ECT treatmentHopkins Verbal Learning Test-Revised
BVMT-RApproximately 30 min after ECT treatmentBrief Visual Memory Test-Revised

Countries

Australia

Contacts

Primary ContactFeng Lin, MD
feng.lin@student.unsw.edu.au+612 9382 8318
Backup ContactColleen Loo, MBBS
+612 9113 2039

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026